PCV13: Effective Against First-Episode CAP in Older Adults

News
Slideshow

The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
ACOG Publishes Revised Guidance on Maternal Immunization for COVID-19, Influenza, and RSV

ACOG Publishes Revised Guidance on Maternal Immunization for COVID-19, Influenza, and RSV

Grace Halsey
September 2nd 2025
Article
Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
September 2nd 2025
Podcast
FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis

FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis

Sydney Jennings
September 2nd 2025
Article
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
September 2nd 2025
Podcast
Efficacy of Apnimed's Novel Oral Formulation Targeting OSA Confirmed in Second Phase 3 Trial / image credit ©Apnimed

Efficacy of Apnimed's Novel Oral Formulation Targeting OSA Confirmed in Second Phase 3 Trial

Grace Halsey
September 2nd 2025
Article
Roche's Investigational Anti-IL-33/ST2 Antibody / image credit ©Sundry Photography/stock.adobe.com

Roche's Investigational Anti-IL-33/ST2 Antibody for COPD Misses Phase 3 Primary Endpoint

Grace Halsey
September 2nd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.